Collaboration - February 9, 2021
Affibody selects Biovian as a CDMO partner for ABY-062
Affibody has selected Biovian Oy as a CDMO partner for ABY-062 recombinant protein for clinical trial use. The agreement covers the technical transfer of production processes and analytics followed by non-GMP and GMP manufacturing of the ABY-062 molecule at Biovian’s facility in Turku, Finland. Analytical method validations, aseptic fill and finish of Drug Product as […]
Clinical Trials - June 15, 2020
Affibody terminates program and announces positive data from another
Affibody has announced the completion of the ABY-039 Phase 1 trial, and the termination of the ABY-039 program due to tolerability observations that would limit the target product profile of subcutaneous high dose once monthly maintentance injections. Based on these observations Alexion has terminated the co-development agreement with Affibody. The termination will become effective June […]
Agreement - May 15, 2020
Affibody enters partnership with Inmagene
Under the terms of the agreement, Affibody will receive a $10 million upfront payment and is eligible to receive up to $215.5 million in additional regulatory and sales milestones, plus royalties on sales in Inmagene’s commercialization territory. Affibody and Inmagene Biopharmaceuticals have announced a strategic partnership to develop and commercialize ABY-035, a bispecific molecule targeting […]
Pharma Business - May 4, 2020
Affibody announces Option Exercise by Daewoong
Affibody has announced that its partner Daewoong, a South Korea-based pharmaceutical company, has exercised an option under the companies’ ongoing collaboration. “We are pleased to announce that our longtime partner Daewoong has decided to exercise their option to develop and commercialize an innovative new half-life extended biotherapeutics product,” says David Bejker, CEO of Affibody. “We […]
Collaboration - September 20, 2019
Affibody and GE Healthcare to collaborate
Affibody has announced a strategic collaboration with GE Healthcare to develop and commercialize Affibody-based PET imaging tracers, with initial focus on HER2 and PD-L1. “The initiation of a strategic collaboration with GE Healthcare around PET imaging tracers reflects the commitment of Affibody to precision medicine and biomarker guided patient treatment. It also underlines the competitiveness […]
Clinical Trials - August 11, 2019
Affibody announces interim analysis in Phase 2 Psoriasis trial
The company has completed a planned 12 week interim analysis in the its Phase 2 proof-of-concept study of its bispecific molecule ABY-035 for moderate-to-severe psoriasis (“AFFIRM 35”). “Our Phase 2 AFFIRM-35 study with ABY-035 has now reached the stage where we are starting to see the first results,” said David Bejker, CEO of Affibody. “These […]
